Literature DB >> 12614187

Database studies in asthma pharmacoeconomics: uses, limitations and quality markers.

Mike Thomas1, Jennifer Cleland, David Price.   

Abstract

Asthma is a common chronic disease resulting in significant morbidity and health resource utilisation, and multiple therapeutic options exist. Clinicians and healthcare providers need accurate information on the clinical and cost- effectiveness of asthma treatments to make informed decisions on management strategies. Randomised, controlled trials demonstrate cause and effect relationships between treatments and outcomes, but their tight entry criteria and strict study protocols mean that their results cannot automatically be generalised or used for economic modelling. There is a need for observational data to examine the effectiveness of alternative interventions in routine practice. Clinical and administrative databases are a possible information source for observational studies, and are increasingly used in asthma clinical, epidemiological and economic research. This paper examines the types of database used, the advantages and limitations of such studies and considers quality markers. High quality database studies can provide important epidemiological and economic information that can be of value in understanding the causes and effective management of asthma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614187     DOI: 10.1517/14656566.4.3.351

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

1.  Prescribing patterns of asthma controller therapy for children in UK primary care: a cross-sectional observational study.

Authors:  Mike Thomas; Tarita Murray-Thomas; Tao Fan; Tim Williams; Stephanie Taylor
Journal:  BMC Pulm Med       Date:  2010-05-14       Impact factor: 3.317

2.  Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy.

Authors:  Isabella Ruggeri; Donatello Bragato; Giorgio L Colombo; Emanuela Valla; Sergio Di Matteo
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-05

3.  Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.

Authors:  Linda Kemp; John Haughney; Neil Barnes; Erika Sims; Julie von Ziegenweidt; Elizabeth V Hillyer; Amanda J Lee; Alison Chisholm; David Price
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-01

Review 4.  Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.

Authors:  David Price; Alison Chisholm; Thys van der Molen; Nicolas Roche; Elizabeth V Hillyer; Jean Bousquet
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

5.  Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.

Authors:  Mike Thomas; David Price; Henry Chrystyn; Andrew Lloyd; Angela E Williams; Julie von Ziegenweidt
Journal:  BMC Pulm Med       Date:  2009-01-02       Impact factor: 3.317

Review 6.  Assessing asthma severity based on claims data: a systematic review.

Authors:  Christian Jacob; Jennifer S Haas; Benno Bechtel; Peter Kardos; Sebastian Braun
Journal:  Eur J Health Econ       Date:  2016-03-01

7.  Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis.

Authors:  Álvaro Flórez-Tanus; Devian Parra; Josefina Zakzuk; Luis Caraballo; Nelson Alvis-Guzmán
Journal:  World Allergy Organ J       Date:  2018-11-12       Impact factor: 4.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.